Evolvence, which recently paid Dh19.2 m (€3.7m) for a stake in Chennai-based epilepsy specialist Anjan Drugs, said it plans to invest $100m (€72m) in Indian pharma firms over the next few years.
Evolvence CEO Khaled Al Muhairy told the paper that: "We are investing with a long-term perspective. India will attract a lot of pharmaceutical research as costs are significantly lower when compared to the West “
In 2008, Evolvence invested $30m in Hyderabad drug delivery specialist Grand Pharma and a further $5m in Bangalore-based cancer research network Health Care Global.
